

Vaccines and Global Health: The Week in Review 27 July 2024 :: Issue 761 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks

Milestones, Perspectives

::::::

Syria - Zero-dose, Under-vaccinated Children

The Big Catch-Up: Syria rolls out initiative to reach millions of children missed during COVID-19 pandemic

Damascus, 23 July 2024 – The Syrian Ministry of Health (MOH), supported by **WHO, UNICEF and Gavi,** the Vaccine Alliance, has launched the **second round of Big Catch-Up** vaccination activity this week.

The Big Catch-Up is an initiative launched by global health partners in April 2023 to address the decline in childhood vaccination rates observed during the COVID-19 pandemic as a result of overburdened health systems and disrupted access to medical care. This is the second phase in Syria, following an initial phase in April this year.

During this round, about 2 million children under the age of five are targeted to be screened, and more than 300,000 are expected to be vaccinated with different childhood vaccines. The activity aims to reach children through fixed sites and mobile vaccination teams across the selected areas of coverage, with over 7,500 health workers deployed.

Additionally, a measles vaccination campaign will be conducted in 68 districts (out of 107) targeting about 2 million children under the age of five regardless of their vaccination status. The implementing districts were selected based on their vaccine coverage rates as well as reported cases of outbreaks.

WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) indicate that in 2023, Syria's coverage of the first dose of measles-containing vaccine rose to 74%, up from 52% in the previous year (2022) but still lower compared to pre-pandemic levels at 76%. Curbing measles outbreaks requires a coverage rate of at least 95%.

To ensure uptake, MOH Syria and partners are also rolling out proactive community engagement activities to promote vaccination of children, including through partnership with community leaders, social and mass media, as well as other influencers.

"The Big Catch-Up initiative in Syria is not only an opportunity to immunize and protect all children up to five years old, including zero-dose children, but is also aimed at strengthening routine immunization from planning to service delivery and to monitoring systems. Gavi and our partners are committed to continue supporting the Ministry of Health towards a strong and resilient national immunization programme, which is the essential pillar for combating disease outbreaks," said Véronique Maeva Fages, the Senior Country Manager for Syria at Gavi...

In Syria, **the first round** managed to screen the vaccination status of more than 1.8 million children and vaccinated zero-dose and unvaccinated children with the needed vaccines. Additionally, **1.8 million received the oral polio vaccine (bOPV) and 1 million received vitamin A regardless of their vaccination status.** Around 7,500 health workers and vaccinators were deployed to more than 1,000 sites to screen children's vaccination status and immunize those who were unvaccinated.

The campaign week for the second round coincides with a joint high-level mission by WHO, UNICEF and Gavi to Syria, which is aimed at understanding the status of the current immunization programme and continuing a dialogue on longer-term sustainable solutions in vaccine procurement and financing. The next round of the Big Catch-Up initiative is slated for October this year.

Syria is one of <u>35 countries currently conducting</u> **Big Catch-Up activities** aimed at addressing gaps in coverage caused by the pandemic that have led to increased outbreaks.

::::::

Pandemic Fund

Pandemic Fund Kickstarts Resource Mobilization with \$667 million from the United States
Germany also pledges \$54 million on margins of G20 Finance Ministers' meeting

RIO DE JANEIRO, July 24, 2024 — **The United States pledged up to \$667 million, and Germany pledged \$54 million to the Pandemic Fund** as it works towards raising at least \$2 billion to meet strong demand from low- and middle-income countries...

The pledges came as the Pandemic Fund launched its <u>Investment Case resource mobilization campaign</u> on the sidelines of the G20 Finance Ministers and Central Bank Governors meeting.

"The Pandemic Fund is making essential investments to strengthen capacity to prevent, prepare for, and respond to disease outbreaks. That's why we are working urgently to raise at least \$2 billion in new funding for the next two years. The Pandemic Fund can use this to catalyze additional resources to fill critical gaps in surveillance, testing, workforce, and surge capacity," said Ajay Banga, World Bank Group President.

G20 Finance and Development Ministers, representatives from multilateral development banks, United Nations agencies, global health initiatives, and Civil Society Organizations expressed strong support for the Pandemic Fund...Partners will come together again at a pledging event on October 31, 2024, hosted by Brazil under its G20 Presidency.

With US\$338 million in grants awarded under the first funding round, that have catalyzed US\$2 billion in additional resources, the Pandemic Fund is supporting:

BOX 1

25

Countries with stronger, One Health surveillance

21+

Countries with stronger AMR surveillance 18

Projects with cross border surveillance

29+

Countries with stronger lab infrastructure 23

Countries with better lab regulatory standards

22+

Countries with expanded/ upskilled multidisciplinary workforce 21

Countries with enhanced local/community-level workforce capacity Priya Basu, Executive Head of the Pandemic Fund, said, "We all have a stake in preventing, detecting, and managing health emergencies. That's the mission of the Pandemic Fund. To maintain momentum, the Pandemic Fund needs a minimum of \$2 billion in new funding for the next two years — a small fraction of the global cost of responding to COVID-19. As we work toward the pledging event on October 31, we call upon all existing donors as well as new funders to help ensure an adequately resourced Pandemic Fund,"

About the Pandemic Fund:

Drawing on lessons from the COVID-19 pandemic, <u>the Pandemic Fund</u> was established in September 2022 as a first-of-its-kind multilateral financing mechanism dedicated to investing in critical pandemic prevention, preparedness and response capacities in low- and middle-income countries.

With seed funding of \$2 billion from 27 contributors, the Pandemic Fund awarded its first round of grants in 2023 to projects that have fostered coordination and collaboration across sectors within countries, across countries, and between domestic and international partners. The Fund's catalytic financing structure has enabled it to mobilize \$6 from international and domestic sources for every dollar granted to projects. For projects in middle income countries and multi-country and regional projects, an even higher combined leverage ratio of almost 9x has been achieved. A second round of funding is set to be awarded later this year.

::::::

HIV - Children

Transforming Vision into Reality

The 2024 Global Alliance Progress Report on Ending AIDS in Children by 2030 22 July 2024 | Technical document

PDF: https://www.unaids.org/sites/default/files/media asset/transforming-vision-into-reality_en.pdf
Overview

This Global Alliance Progress Report on Ending AIDS in Children by 2030 is the **first comprehensive** pediatric report on the global alliance countries since 2021. The report details progress, gaps and a way forward for the 12 countries (Angola, Cameroon, Cote d'Ivoire, Democratic Republic of Congo, Kenya, Mozambique, Nigeria, South Africa, Tanzania, Uganda, Zambia, Zimbabwe).

Ending AIDS in children by 2030 is possible, but the pace of progress needs to be accelerated. The report shows that only 48% of children living with HIV globally and in Global Alliance countries achieved viral load suppression, versus 73% of adults globally and 79% in Global Alliance countries. Close to 600 000 children globally were not receiving life-saving treatment in 2023, including 400 000 (close to 70%) living in the 12 Global Alliance countries.

A renewed commitment to closing the gaps to HIV prevention, testing, treatment, and care for children and adolescents is needed as well as enhanced support for pregnant and breastfeeding mothers, and women of reproductive age. We must innovate differently, putting communities at the center to provide accelerated access to HIV prevention, testing, treatment, and care for children and adolescents, and provide robust support for pregnant and breastfeeding mothers.


Conclusion

Taken together, current trends lead to two key conclusions.

First, marked progress in reducing new HIV infections and AIDS-related deaths among children and adolescents is feasible. Second, progress varies considerably among Global Alliance countries, with increases in cases reported in some countries. Current trends underscore the urgency of accelerating progress in each of the four strategic pillars of the Global Alliance, with specific attention to closing inequalities in service access and outcomes.

This report underscores the importance of sustained global and local efforts, enhanced community engagement and robust monitoring and adaptation of strategies. Context-specific pathways and action plans to close gaps in efforts to end AIDS need to be developed and implementation carefully monitored. Planning is also critical to ensure the long-term sustainability of HIV programmes for children and adolescents.

Figure 2 Numbers of children living with HIV 0–14 years old, new HIV infections and AIDS-related deaths among children living with HIV 0–14 years old in Global Alliance countries with available data, 2023



Source: UNAIDS epidemiological estimates, 2024 (https://aidsinfo.unaids.org).

Political leadership and commitment are essential. In addition to putting sound policies in place, essential funding must be mobilized, since substantial gaps persist between the resources needed to end AIDS in children and the resources currently available.

In 2024, the Coalition for Children Affected by AIDS estimated that the global resource gap for services to prevent vertical HIV transmission amounted to US\$ 89 million, while the amount available for antiretroviral therapy for children was US\$ 231 million short of what is needed. Reaching the goal of ending AIDS in children requires urgent steps to close these resource gaps (50).

::::::

<u>Unfinished business: only the urgent and accelerated delivery of HIV services will keep the promise of ending AIDS in children by 2030</u>

Despite significant gains in many countries, critical gaps continue to undermine efforts to end AIDS in children

22 July 2024 *Joint News Release* Geneva/Munich

Despite progress made in reducing HIV infections and AIDS-related deaths among children, a new report released today by the Global Alliance for Ending AIDS in Children by 2030 shows that an **urgent scale up of HIV services in countries worst affected by the pandemic is required to end AIDS by 2030.**

The report, <u>Transforming Vision Into Reality</u>, shows that programmes targeting vertical transmission of HIV have averted 4 million infections among children aged 0-14 years old since 2000. Globally, new HIV infections among children aged 0-14 years old have declined by 38% since 2015 and AIDS-related deaths have fallen by 43%.

Among the twelve Global Alliance countries, several have achieved strong coverage of lifelong antiretroviral therapy among pregnant and breastfeeding women living with HIV, with Uganda nearing 100%, United Republic of Tanzania at 98%, and South Africa at 97%. Mozambique has achieved 90% coverage, with Zambia at 90%, Angola at 89%, Kenya at 89%, Zimbabwe at 88%, and Cote d'Ivoire at 84%.

"I applaud the progress that many countries are making in rolling out HIV services to keep young women healthy and to protect babies and children from HIV," said UNAIDS Executive Director, Winnie Byanyima. "With the medicines and science available today, we can ensure that all babies are born – and remain – HIV-free, and that all children who are living with HIV get on and stay on treatment. Services for treatment and prevention must be ramped up immediately to ensure that they reach all children everywhere. We cannot rest on our laurels. The death of any child from AIDS related causes is not only a tragedy, but also an outrage. Where I come from, all children are our children. The world can and must keep its promise to end AIDS in children by 2030."...

"In the fight against HIV, we must do a much better job for children," said Peter Sands, Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which provides funding for HIV programmes in over 100 countries through a country-led partnership model. "In support of national programmes, we have been procuring the latest dolutegravir-based paediatric treatment regimens at negotiated prices. Our investments in laboratory systems are helping ensure exposed infants are rapidly tested and that those that test positive are quickly initiated on age-appropriate antiretroviral treatment. Differentiated testing and treatment approaches are helping close the diagnostic gap and ensuring more child-centred service delivery."...

::::::

Featured Journal Content

The Lancet

Jul 27, 2024 Volume 404 Number 10450 p311-404 https://www.thelancet.com/journals/lancet/issue/current Editorial

Dengue: the threat to health now and in the future

The Lancet

2024 is the worst year for <u>dengue cases on record</u>. As of July 23, over 10 million cases of dengue have been reported from 176 countries across all WHO regions (although the Americas account for most cases), with more than 24 000 severe cases and 6508 deaths. This figure already surpasses the number of cases in 2023, which was also a record year. There is no doubt that dengue, a vector-borne disease caused by four serologically related viruses, is a major infectious disease threat to health. Over the past two decades, there has been a tenfold increase in reported cases, and even this figure is likely an underestimate. It is the only infectious disease for which annual mortality is rising (80% of infections are asymptomatic or produce mild febrile illness but the case fatality rate increases during outbreaks). Rightly so, WHO has classified dengue as a grade 3 emergency (ie, requiring a major to maximal WHO response). Upcoming monsoons in the tropics and northern hemisphere are likely to drive a steep increase in dengue cases over the coming months.

The surge in cases and the geographical expansion of the virus are, in many ways, man-made. **The triad of urbanisation, climate change, and the movement of people and goods is facilitating the spread of dengue and its Aedes mosquito vector**. More extreme El Niño and La Niña events have led to heavy precipitation, humidity, and rising temperatures favouring vector reproduction and virus transmission. The <u>2023 Lancet Countdown on health and climate change</u> estimated that rising temperature alone has already increased the global transmission potential of Aedes aegypti by 42·7% between the 1950s and the 2010s, with the impact expected to increase further in the future. As virus cocirculation increases, so too will the risk of secondary infections, and with that, also the risk of more severe dengue, hospitalisations, and deaths.

An emerging concern is Africa, where active transmission of dengue virus has been reported in 15 countries in the past year. The continent has little clinical experience with the disease, many primary infections go undetected, and funding constraints hinder preparedness and response. Already, 50% of the population lives in unplanned urban settings, a proportion due to rise to 62% by 2050. Mitigation measures to tackle dengue upfront as part of urban development will be crucial. Following a severe outbreak in Burkina Faso in 2023, and the declines in malaria cases, which would have masked dengue in the past, there is far more awareness of dengue and of the need to address response and reporting.

But generally, dengue does not receive anywhere near the attention and resources it merits. Outbreaks can overwhelm health systems and inflict a huge economic burden, yet limited WHO funds for dengue control come from the Director General's Emergency Fund, and further funding from countries has not been forthcoming. The seasonality of dengue and the periodic nature of outbreaks means that control measures are often implemented reactively, during the peak in cases—too little, too late. A WHO resolution on dengue to get the much-needed commitment of countries to address this growing problem would be one positive step. Countries should be encouraged to propose such a draft ahead of the 2025 WHO Executive Board Meeting.

If the spread of dengue virus is to be halted, there needs to be a shift from ad-hoc responses to isolated outbreaks towards long-term, integrated programming between relevant sectors. An increase in funding is required for a combination of dengue programmes that include prevention, management and treatment, and effective surveillance. Embedding dengue prevention in urban planning is a key health measure in climate change adaptation.

Several exciting new dengue control technologies, not least new vaccines, should be able to help with prevention (although less likely with control) of dengue outbreaks. Together, such measures offer a way for controlling, and then reversing, the spread of dengue. When such programming also includes community-level initiatives, it can lead to sustainable behaviour change that results in positive effects on health outcomes. Many benefits would extend to other arboviruses, such as chikungunya and the newly emerging Oropouche virus.

How exactly can we best address the immediate threat of current outbreaks while tackling the longer-term headwinds of climate change, urbanisation, and increased mobility that will continue to drive dengue? What co-benefits might be gleaned? A Lancet Commission on dengue and other Aedestransmitted viral diseases will attempt to answer these questions. But what is clear is the need for a multipronged and multidisciplinary approach; there is no easy solution to dengue.

::::::

Polio - PHEIC

Polio this week as of 24 July 2024 - GPEI

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: one WPV1 case and nine positive environmental samples
- Angola: two cVDPV2-positive environmental samples
- DRC: one cVDPV2 case
- Ethiopia: five cVDPV2 cases and one positive environmental sample
- Somalia : one cVDPV2 case
- South Sudan: one cVDPV2-positive environmental sample
- Yemen: 11 cVDPV2 cases

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

WHO & Regional Offices [to 27 July 2024]

https://www.who.int/news

Selected News/Announcements/Statements

25 July 2024 News release

WHO teams up with IOC and France to support healthy Paris Olympics

24 July 2024 News release

Fifteen children from Gaza to receive urgent medical care in Spain

<u>Hunger numbers stubbornly high for three consecutive years as global crises deepen: UN report</u>

1 in 11 people worldwide faced hunger in 2023, 1 in 5 in Africa

24 July 2024 Joint News Release Rio de Janeiro

Around 733 million people faced hunger in 2023, equivalent to one in eleven people globally and one in five in Africa, according to the latest <u>State of Food Security and Nutrition in the World (SOFI) report</u> published today by five United Nations specialized agencies.

The annual report, launched this year in the context of the <u>G20 Global Alliance against Hunger and Poverty Task Force</u> Ministerial Meeting in Brazil, warns that the world is falling significantly short of achieving Sustainable Development Goal (SDG) 2, <u>Zero Hunger</u>, by 2030. The report shows that the world has been set back 15 years, with levels of undernourishment comparable to those in 2008-2009.

Despite some progress in specific areas such as stunting and exclusive breastfeeding, an alarming number of people continue to face food insecurity and malnutrition as global hunger levels have plateaued for three consecutive years, with between 713 and 757 million people undernourished in 2023—approximately 152 million more than in 2019 when considering the mid-range (733 million)...

22 July 2024 Joint News Release

<u>Unfinished business: only the urgent and accelerated delivery of HIV services will keep the promise of ending AIDS in children by 2030</u>

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: Seventy-fourth session of the WHO Regional Committee for Africa

26 - 30 August 2024 Brazzaville, Republic of Congo

WHO Region of the Americas PAHO

:: 25 Jul 2024

World Hepatitis Day: PAHO calls for expanded access to diagnosis and treatment

Washington, DC, July 25, 2024 (PAHO) – In the run up to World Hepatitis Day (July 28), the Pan American Health Organization (PAHO) is urging countries to expand access to testing and treatment for viral hepatitis, which affects more than ten million people in the Americas, only 23% of whom are diagnosed. From the five types of hepatitis...

:: 24 Jul 2024

<u>PAHO Director welcomes Brazil's proposal for Global Alliance against Hunger and Poverty within G20</u>

Rio de Janeiro, July 24, 2024 - In a meeting with the President of the Republic of Brazil, Luiz Inácio Lula da Silva, the Director of the Pan American Health Organization (PAHO) and World Health Organization (WHO) Regional Director for the Americas, Dr. Jarbas Barbosa, congratulated the Brazilian government for its proposal to create a Global...

:: 24 Jul 2024

As global cases of whooping cough rise, PAHO calls on countries to strengthen surveillance and increase vaccination

Washington D.C. 24 July 2024 (PAHO) – In light of an increase in whooping cough (pertussis) cases globally and in some countries of the Americas, the Pan American Health Organization (PAHO) has issued an epidemiological alert, calling on countries to strengthen surveillance and ensure constant monitoring of vaccination coverage in children....

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 22 July 2024 Statement

Statement – Ending AIDS by 2030: We can keep the promise

:: 22 July 2024 Statement

Statement - HIV and TB: Let's nurture the incredible progress we have made so far

WHO Eastern Mediterranean Region EMRO

:: The Big Catch-Up: Syria rolls out initiative to reach millions of children missed during COVID-19 pandemic

23 July 2024

:: WHO strengthens public health response to substance use in Afghanistan 23 July 2024

WHO Western Pacific Region

:: 24 July 2024

Japan supports WHO's work to improve health services and emergency response

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

26 July 2024

WHO's Operational Update on Health Emergencies - June 2024

Key figures on WHO's work in emergencies (as of 15 June 2024)

WHO is currently responding to 43 graded emergencies across the world, including:

- 9 Grade-3 emergencies
- 7 protracted Grade-3 emergencies
- 12 Grade-2 emergencies
- 12 protracted Grade-2 emergencies
- 3 Grade-1 emergencies

In 2024, US\$ 31 million were released by WHO's Contingency Fund for Emergencies (CFE) to 22 health emergencies. The largest allocations were for the Dengue Global Outbreak, Israel/occupied Palestinian territories hostilities and the Northern Ethiopia Humanitarian Response.

The Global Outbreak Alert and Response Network (GOARN) has supported 28 deployments in 2024 (of which five started in 2023 and ended in 2024). **As of mid-June 2024, the highest number of GOARN deployments were in response to the escalation of violence in Israel and occupied**

Palestinian territories (eleven), the Greater Horn of Africa Drought and Food Insecurity (five), and the cholera outbreak in Zambia (three).

OpenWHO.org totaled 8.7 million enrolments across 280 online public health courses, with learning available in 72 national and local languages. To date, there have been 342 000 enrolments in 2024.

In 2024, Standby Partners have supported WHO's response to 9 graded emergencies through the deployment of 21 new deployments of surge personnel to 15 WHO offices. WHO is an active member of the Standby Partner Network and the International Humanitarian Partnership.

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

22 July 2024 | Dengue - Iran (Islamic Republic of)

Situation at a glance

On 14 June 2024, the Ministry of Health and Medical Education (MoHME) of **Iran reported the first two locally acquired cases of dengue recorded in the country**. Local transmission of dengue within the community was confirmed in Bandar-Lengheh, Hormozgan Province, southern Iran. As of 17 July 2024, the total number of locally acquired (autochthonous) dengue cases in the country has risen to 12, all reported in Bandar-Lengheh...

Iran's MoHME has enacted measures to strengthen hospital readiness. The World Health Organization (WHO) is supporting the MoHME to enhance surveillance, distributing medical and rapid diagnostic supplies, providing training, and organizing risk communication and community engagement (RCCE) activities.

On 16 May 2024, WHO reassessed the global risk of dengue as high, reiterating that dengue remains a global public health threat. The risk for Iran is also high due to the presence of the vector in the country, favourable climate conditions for the vector and the movement of people from countries with ongoing dengue outbreaks and endemic areas to Iran.

::::::

Weekly Epidemiological Record

https://www.who.int/publications/journals/weekly-epidemiological-record

Vol. 99, Nos. 30/31, pp. 395-406 26 July 2024

PDF: https://iris.who.int/bitstream/handle/10665/378268/WER9930-31-eng-fre.pdf

395 WHO's Health Emergencies Programme: acute emergencies monthly summary – June 2024

400 Meeting of the Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC), February–March 2024

:::::

New WHO Publications

https://www.who.int/publications/i Selected 22 July 2024

Improving access to medicines for neurological disorders

22 July 2024

<u>Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections,...</u>

Overview

This report is the first of a series of biennial progress reports on the implementation of the Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030.

Key messages

- the latest data show that new infections and deaths are not declining fast enough;
- gains have been made in expanding service access across all 3 disease areas;
- yet many indicators remain off-track to achieve the 2025 and 2030 global targets; and
- countries need to clearly focus on sustainability planning across the 3 disease areas.

22 July 2024

Guidelines for HIV post-exposure prophylaxis

::::::

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

<u>Press Announcements</u> No new digest content identified.

FDA VRBPAC

<u>Advisory Committee Calendar</u> No meetings appear on calendar.

CDC/ACIP [U.S.] [to 27 July 2024]

http://www.cdc.gov/media/index.html

Latest News

CDC Confirms Three Human Cases of H5 Bird Flu Among Colorado Poultry Workers

Three additional human cases of highly pathogenic avian influenza (HPAI) A(H5) ("H5 bird flu") virus infection have been confirmed by the Centers for Disease Control and Prevention (CDC) in association...

July 25, 2024

ACIP Meetings

Next ACIP Meeting
October 23-24, 2024

MMWR Weekly

https://www.cdc.gov/mmwr/index2023.html

July 25, 2024 / No. 29

PDF of this issue

- <u>Progress Toward Elimination of Mother-to-Child Transmission of Hepatitis B Virus Region of the Americas</u>, 2012–2022
- Notes from the Field: Health Monitoring, Testing, and Case Identification Among Persons Exposed to Influenza A(H5N1) Michigan, 2024

::::::

Europe

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news

News & Press Releases

<u>Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-</u> 25 July 2024

26 July 2024

14 new medicines recommended for approval; another 11 medicines recommended for extension of therapeutic indications

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

<u>HIV stigma in the healthcare setting: Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia</u>

23 Jul 2024

ECDC and the European AIDS Clinical Society (EACS) recently worked together to acquire knowledge on the occurrence of HIV-related stigma and discrimination among people working in various healthcare settings in Europe and Central Asia. A survey was developed by a multi-stakeholder group, based on an existing questionnaire.

::::::

Africa CDC [to 27 July 2024]

https://africacdc.org/

Press Releases, Statements [Selected]

Africa CDC and Africa Public Health Foundation Forge Strategic Partnership to Strengthen Health Systems

Nairobi, Kenya. July 25, 2024 – The Africa Centres for Disease Control and Prevention (Africa CDC) and Africa Public Health Foundation (APHF) have signed an agreement to support strengthening health systems in Africa Union Member States.

APHF was established to enable investments in public health activities that support Africa CDC's goals and objectives across the continent. It's main operational vectors include resource mobilisation, grants management, advocacy for improved policies, private sector engagement and contributing to the analysis of public health data...

The Agreement outlines the collaboration modalities between the two institutions, with the priority areas articulated in the Africa CDC strategy as a reference. These include **strengthening public health institutions and the workforce, expanding local manufacturing of vaccines,**

diagnostics, and therapeutics, and building partnerships with critical stakeholders within the broader health ecosystem
:::::: ::::::
China CDC http://www.chinacdc.cn/en/
National Health Commission of the People's Republic of China [to 27 July 2024] http://en.nhc.gov.cn/ News
No new digest content identified.
National Medical Products Administration – PRC [to 27 July 2024] http://english.nmpa.gov.cn/ News No new digest content identified.
China CDC CCDC Weekly Reports: Current Volume (6) 2024-07-26 / No. 30WORLD HEPATITIS DAY ISSUE View PDF of this issue - Vital Surveillances: Trends and Age-Period-Cohort Effect on Acute Hepatitis B Incidence — China, 2005–2021 - Review: Developing a Research Network of Early Warning Systems for Infectious Diseases Transmission Between China and Australia
:::::: ::::::
Contents [click to move among sections] :: Milestones, Perspectives :: WHO :: Organization Announcements :: Journal Watch :: Pre-Print Servers
:::::: :::::
Organization Announcements

Paul G. Allen Frontiers Group [to 27 July 2024]

https://alleninstitute.org/news-press/

News

No new digest content identified.

BMGF - Gates Foundation [to 27 July 2024]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 27 July 2024]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people News: Articles and Publications

No new digest content identified.

CARB-X [to 27 July 2024]

https://carb-x.org/

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 27 July 2024]

http://cepi.net/ Latest News News

CEPI appoints Aurélia Nguyen as Deputy CEO

25 Jul 2024

...Aurélia joins CEPI from Gavi, the Vaccine Alliance – where she held roles including Chief Programme Officer and Managing Director of the Covax Facility. Aurélia has a proven track record in driving the design of vaccine programmes and delivery of new vaccines as well as extensive leadership experience with a particular focus on gender and diversity.

In her new role as Deputy CEO she will support CEPI CEO Dr Richard Hatchett and the CEPI team in advancing CEPI's five-year strategy, known as CEPI 2.0, which will help Prepare, Transform and Connect the world so that it can respond to the next Disease X threat in as little as 100 days...

100 Days Mission

The 100 Days Mission - how close are we?

23 Jul 2024

Centralised Laboratory Network

Global vaccine standardisation group discuss progress in Rome

22 Jul 2024

CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 27]

July 2024]

https://cioms.ch/

News; Publications; Events No new digest content identified.

DARPA - Defense Advanced Research Projects Agency [U.S.] [to 27 July 2024

https://www.darpa.mil/news

News

No new digest content identified.

Duke Global Health Innovation Center [to 27 July 2024]

https://dukeghic.org/

News

No new digest content identified.

EDCTP [to 27 July 2024]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials News

No new digest content identified.

Emory Vaccine Center [to 27 July 2024]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

European Vaccine Initiative [to 27 July 2024]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

Evidence Aid [to 27 July 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

http://www.evidenceaid.org/

Resources [Selected]

Medical and Psychosocial Care of Paediatric Refugees

Added July 27, 2024

Access to and engagement with health services among disadvantaged populations Added July 26, 2024

mHealth applications for the 2014-2015 West Africa Ebola outbreak

Added July 25, 2024

Fondation Merieux [to 27 July 2024]

http://www.fondation-merieux.org/

News, Events

No new digest content identified.

Gavi [to 27 July 2024]

https://www.gavi.org/

Press Releases

23 July 2024

The Big Catch-Up: Syria rolls out initiative to reach millions of children missed during COVID-19 pandemic

22 July 2024

61,374 girls in Timor-Leste to receive HPV vaccine to combat cervical cancer

GE2P2 Global Foundation [to 27 July 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review June 2024
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 25 July 2024 Issue 21

GHIT Fund [to 27 July 2024]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 27 July 2024]

https://www.theglobalfund.org/en/news/

News Releases

21 July 2024

<u>CIFF To Propel PrEP Revolution with up to US\$2 Million for Immediate Access to PrEP</u> Rings

The Children's Investment Fund Foundation (CIFF), in partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), announced on 21 July at the 25th International AIDS Conference an initiative of up to US\$2 million over t...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 27 July

2024]

https://www.glopid-r.org/news/

News

No new digest content identified.

Hilleman Laboratories [to 27 July 2024]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 27 July 2024]

https://www.hhmi.org/news

Press Room

HHMI Invests Over \$300 Million in 26 New Investigators

July 23, 2024

Scientists hailing from 19 institutions across the US will join HHMI's community of Investigators in pursuit of groundbreaking research.

Human Immunome Project [nee Human Vaccines Project] [to 27 July 2024]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

IAVI [to 27 July 2024] https://www.iavi.org/
News, Features
IAVI Report

The ties that bind

July 23, 2024

Assessing two decades of a European-African research partnership with an anxious eye on the future.

INSERM [to 27 July 2024]

https://www.inserm.fr/en/home/

Press Releases

Fighting leukaemia by targeting its stem cells

24 Jul 2024

Acute myeloid leukaemia is one of the deadliest cancers. Leukaemic stem cells responsible for the disease are highly resistant to treatment. A team from the University of Geneva (UNIGE), University Hospital of Geneva (HUG), and Inserm has made a breakthrough by identifying some of the genetic and energetic characteristics of these stem cells. Notably, a specific iron utilisation process. This process could be blocked, leading to the death or weakening of these stem cells without affecting healthy cells. These results, published in Science Translational Medicine, pave the way for new therapeutic strategies.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 27 July 2024]

https://www.ich.org/

News/Pubs/Press Releases [Selective]

<u>Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.</u>

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Public consultation dates [announced to date]:

NMPA, China - Deadline for comments by 12 October 2024 TFDA, Chinese Taipei - Deadline for comments by 30 September 2024 ANVISA, Brazil - Deadline for comments by 24 August 2024 MHLW/PMDA, Japan - Deadline for comments by 28 July Republic of Korea - Deadline for comments by 15 July 2024

ICRC [to 27 July 2024]
https://www.icrc.org/en/whats-new
What's New [Selected]
No new digest content identified.

IFFIm

http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

IFRC [to 27 July 2024]
http://media.ifrc.org/ifrc/news/press-releases/
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 27 July 2024] https://www.pasteur.fr/en/press-area Press Documents No new digest content identified.

ISC / International Science Council [to 27 July 2024]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates
blog 24 July 2024

WorldFAIR: Continuing to transform data to tackle complex challenges in a follow-up project

On a mission to transform data and enable effective cross-domain collaboration, the ISC Affiliated Body CODATA marks the completion of its flagship initiative WorldFAIR and releases policy recommendations, diverse case studies and further guidance to bring us closer to the vision of FAIR (Findable, Accessible, Interoperable, and Reusable) data. The follow up WorldFAIR+ project is planned to sustain and expand on this legacy...

International Union of Immunological Societies (IUIS)

https://iuis.org/ News/Events [Selected] No new digest content identified.

IVAC [to 27 July 2024]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [to 27 July 2024] http://www.ivi.int/ *IVI News & Announcements*

IVI appoints Douglas Shaffer Deputy Director General

July 24, 2024 – SEOUL, Republic of Korea – IVI is pleased to announce that Dr. Douglas Shaffer will join as IVI's Deputy Director General of Global Affairs & Communications on August 26, 2024, based in Nairobi, Kenya. With over 27 years of service in the United States Government, including 22 years in sub-Saharan Africa, Dr. Shaffer brings extensive experience in clinical research, medical education, regulatory strengthening, capacity building, and global health diplomacy...

Johns Hopkins Center for Health Security [to 27 July 2024]

https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

MSF/Médecins Sans Frontières [to 27 July 2024]

http://www.msf.org/ Latest [Selected Announcements] Pakistan

Persistence reaps rewards in overcoming hepatitis C in Karachi

Project Update 24 Jul 2024

HIV/AIDS

MSF at AIDS 2024

Event 22 Jul 2024

Gaza-Israel war

A day in the life at the last remaining hospital in southern Gaza

Voices from the Field 22 Jul 2024

Conflict in Sudan

A war on people: the human cost of conflict and violence in Sudan

Report 22 Jul 2024

National Academy of Medicine - USA [to 27 July 2024]

https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 27 July 2024]

https://www.nationalacademies.org/newsroom?

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 27 July 2024]

https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 27 July 2024] http://www.nih.gov/

New Releases

Tuesday, July 23, 2024

<u>Exploratory analysis associates HIV drug abacavir with elevated cardiovascular disease</u> <u>risk in large global trial</u>

Findings add to body of evidence on cardiovascular risk factors for people with HIV.

Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy

July 23, 2024 — NIH-sponsored study supports cabotegravir use throughout period of reproductive potential.

NIH findings shed light on risks and benefits of integrating AI into medical decisionmaking

July 23, 2024

AI model scored well on medical diagnostic quiz, but made mistakes explaining answers.

PATH [to 27 July 2024]

https://www.path.org/media-center/

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 27 July 2024]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

UNAIDS [to 27 July 2024]

http://www.unaids.org/en News, Stories, Updates

<u>Developing the 2030 recommended HIV targets: framing the future of the HIV response</u> 26 July 2024

UNAIDS has launched the 2030 target-setting process that will provide the framework for the next Global AIDS Strategy. A Global Targets Task Team (GTT) composed of 33 experts from governments, civil society and communities, donors, multilateral organizations and academic public health experts will propose the targets building on the targets set for 2025. The Global Task Team is co-chaired by Chewe Luo, former Director HIV at UNICEF and Michel Kazatchkine, former Executive Director at the Global Fund.

The targets and strategy will underpin and inform the June 2026 High Level meeting on AIDS. The 2030 HIV targets will provide milestones within the SDG 2030 targets of reducing new HIV infections and AIDS-related deaths.

As highlighted in the <u>July 2024 Global AIDS Update – the Urgency of Now: AIDS at a crossroad</u>s, there will be millions of people living with HIV in 2030 and beyond. The next set of targets will focus on the services and systems that countries need to have in place to ensure a sustainable country-owned response after 2030.

UNICEF [to 27 July 2024]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements

Press release 25 July 2024

Almost 300,000 children threatened by severe acute malnutrition in six drought-affected countries in Southern Africa – UNICEF

NAIROBI/NEW YORK, 25 July 2024 – The severe drought that has impacted large swathes of Southern Africa is threatening the lives of hundreds of thousands of children in the six worst-affected countries, UNICEF said today. This includes more than 270,000 children who are expected to suffer from life-threatening severe acute malnutrition (SAM) in...

Statement 24 July 2024

<u>Statement by UNICEF Executive Director Catherine Russell on the situation in the Gaza Strip</u>

NEW YORK, 24 July 2024 - "With each passing week, children and families face new horrors in the Gaza Strip. The devastating attacks on schools and internally displaced sites continue, reportedly killing hundreds more Palestinians, many of them women and children, and leaving already overwhelmed hospitals buckling under the strain. "We see children...

Press release 24 July 2024

Rising heat across Europe and Central Asia kills nearly 400 children a year

GENEVA, 24 July 2024 – Rising temperatures across Europe and Central Asia killed an estimated 377 children in 2021 – according to a new analysis of data from 23 countries published today by UNICEF.

Beat the Heat: Child Health Amid Heatwaves in Europe and Central Asia finds that half of these children died from heat-related illnesses in their first...

Press release 24 July 2024

<u>Hunger numbers stubbornly high for three consecutive years as global crises deepen: UN report</u>

RIO DE JANEIRO, 24 July 2024 – Around 733 million people faced hunger in 2023, equivalent to one in eleven people globally and one in five in Africa, according to the latest State of Food Security and Nutrition in the World (SOFI) report published today by five United Nations specialized agencies. The annual report, launched this year in the...

Press release 22 July 2024

<u>Unfinished business: only urgent and accelerated delivery of HIV services will keep the promise of ending AIDS in children by 2030</u>

GENEVA/MUNICH, 22 July 2024 - Despite progress made in reducing HIV infections and AIDS-related deaths among children, a new report released today by the Global Alliance for Ending AIDS in Children by 2030 shows that an urgent scale up of HIV services in countries worst affected by the pandemic is required to end AIDS by 2030. The report,...

Unitaid [to 27 July 2024] https://unitaid.org/ Featured News No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 27 July 2024]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 27 July 2024]

https://www.vaccineacceptance.org/ Announcements, Blog No new digest content identified.

Vaccine Confidence Project [to 27 July 2024]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 27 July 2024]

http://www.chop.edu/centers-programs/vaccine-education-center
News

Vaccine Update for Providers - July 2024

Announcements: Fall webinar registration open, program changes reminder September webinar registration now open The next "Current Issues in Vaccines" webinar is scheduled for Sept. 11, 2024, at noon ET. Dr. Offit will be joined by Dr. Lori Handy to discuss the June ACIP meeting in a presentation titled, "Implementing ACIP Recommendations this Fall." Find out more or register today...

Wellcome Trust [to 27 July 2024]

https://wellcome.org/news/all News. Opinion, Reports No new digest content identified.

The Wistar Institute [to 27 July 2024]

https://www.wistar.org/news/press-releases

Press Releases

Wistar to Honor 2023 Nobel Prize Winner Dr. Katalin Karikó

Helen Dean King Award Ceremony Recognizes the Power of Women in Science
PHILADELPHIA — (July 25, 2024) — The Wistar Institute honors 2023 Nobel Prize laureate in
Physiology or Medicine Katalin Karikó, Ph.D., as the 2024 Helen Dean King Award recipient. Dr. Karikó,
professor at the University of Szeged in Hungary and adjunct professor of Neurosurgery at the
University of Pennsylvania, is this year's Helen Dean King Award winner and will speak at the annual
event at noon (ET) at The Wistar Institute on October 8, 2024.

World Bank [to 27 July 2024]

http://www.worldbank.org/en/news/all

All News [Selected]

Pandemic Fund Kickstarts Resource Mobilization with \$667 million from the United States

Germany also pledges \$54 million on margins of G20 Finance Ministers' meeting RIO DE JANEIRO, July 24, 2024 — The United States pledged up to \$667 million, and Germany pledged \$54 million to the Pandemic...

Date: July 24, 2024 Type: Press Release

WFPHA: World Federation of Public Health Associations [to 27 July 2024]

https://www.wfpha.org/ Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 27 July 2024]

https://www.wma.net/news-press/press-releases/

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [to 27 July 2024]

https://www.oie.int/en/ Press Releases, Statements No new digest content identified. ::::::

ARM [Alliance for Regenerative Medicine] [to 27 July 2024]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

BIO [to 27 July 2024]

https://www.bio.org/press-releases

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 27 July 2024]

http://www.dcvmn.org/
News; Upcoming events

ANNUAL GENERAL MEETING 2024

October 16 - 18, 2024 São Paulo, Brazil

ICBA – International Council of Biotechnology Associations [to 27 July 2024]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [to 27 July 2024]

https://ifpma.org/

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 27 July 2024]

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)

Pharmaceutical innovation drives progress, and deserves reward, with intellectual property playing a key role in its protection. Expanding access to these innovations after rewarding them is crucial for public health. In well-functioning markets, generic and biosimilar medicines provide affordable, quality-assured therapeutic options enabling widespread access without compromising safety, efficacy, or quality. This balance supports Universal Health Coverage, reduces financial vulnerability, and ensures sustainable healthcare systems, contributing to Sustainable Development Goals 1, 3, and 10.

PhRMA [to 27 July 2024]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

AstraZeneca

<u>Press Releases</u> - No new digest announcements identified.

Bavarian Nordic

<u>Latest News</u> - No new digest announcements identified.

Bharat Biotech

<u>Press Releases</u> - No new digest announcements identified.

BioCubaFarma – Cuba

<u>Últimas Noticias</u> - - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

<u>Press Releases</u> - No new digest announcements identified

Boehringer

<u>Press Releases</u> - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

<u>Latest News</u> - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

https://sputnikvaccine.com/ - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

23 July 2024

<u>ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1</u>

EuBiologics, S Korea

<u>News</u> - No new digest announcements identified.

IMBCAMS, China

<u>Home</u> - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants July 23, 2024

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

<u>News</u> - No new digest announcements identified.

Novavax

<u>Press Releases</u> - No new digest announcements identified.

Pfizei

<u>Recent Press Releases</u> - No new digest announcements identified

R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur

<u>Press Releases</u> - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

<u>Press Releases</u> - No new digest announcements identified

SK Biosciences

<u>Press Releases</u> - No new digest announcements identified

Takeda

<u>Newsroom</u> - No new digest announcements identified.

Valneva

Press Releases

July 22, 2024

<u>CEPI Expands Partnership with Valneva with a \$41.3 Million Grant to Support Broader</u> Access to the World's First Chikungunya Vaccine

- Valneva to receive up to \$41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®
- Funding will support clinical trials in vulnerable groups, such as children and pregnant women
- Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICs
- IXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe

Vector State Research Centre of Viralogy and Biotechnology

<u>Home</u> - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some

editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

AMA Journal of Ethics

Volume 26, Number 7: E507-590 July 2024

https://journalofethics.ama-assn.org/issue/harm-reduction-and-opioid-use-disorder

Harm Reduction and Opioid Use Disorder

Despite severe punishments and high rates of inequitable incarceration, unprecedented numbers of opioid-related deaths persist in the United States. The US has implemented few policies that align needs of communities, needs of individuals with opioid use disorder (OUD), and clinical evidence. Evidence-based harm reduction practices hold promise to help advance domestic approaches to thinking of OUD treatment as a human right, but successful implementation of harm reduction interventions relies heavily on care continuity and can still be thwarted by a so-called "War on Drugs." This theme issue follows our August 2020 issue, Opioids and Public Health, and specifically considers harm as a concept in need of careful, case-specific attention and reduction as an intervention or set of interventions that are part of a safety net to curb opioid-related morbidity and mortality.

American Journal of Human Genetics

Jul 11, 2024 Volume 111 Issue 7 p1241-1494 https://www.cell.com/ajhg/current

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Clinical genome sequencing (cGS) can provide a precision diagnosis for individuals with a suspected rare genetic disease and can promote improved, personalized care. Despite recognition of the importance of cGS for reaching a diagnosis, individuals residing in areas with reduced resources have limited access to testing options. In a move towards equitable access to cGS, the iHope Program provided cGS to $\sim 1,000$ individuals with a suspected rare genetic disease and constrained access to molecular testing in either low- or middle-income countries (LMICs) or high-income countries (HICs).

American Journal of Infection Control

July 2024 Volume 52 Issue 7 p745-864 http://www.ajicjournal.org/current [Reviewed earlier]

American Journal of Preventive Medicine

July 2024 Volume 67 Issue 1 p1-174 https://www.ajpmonline.org/current

[Reviewed earlier]

American Journal of Public Health

July 2024 114(7) http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 1 (Jul 2024) https://www.ajtmh.org/view/journals/tpmd/111/1/tpmd.111.issue-1.xml [Reviewed earlier]

Annals of Internal Medicine

July 2024 Volume 177, Issue 7 https://www.acpjournals.org/toc/aim/current [Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 332 July 2024 https://www.sciencedirect.com/journal/artificial-intelligence/vol/332/suppl/C [Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/ (Accessed 27 July 2024) [No new digest content identified]

BMC Health Services Research

http://www.biomedcentral.com/bmchealthservres/content (Accessed 27 July 2024)

<u>Expanding vaccination competencies to community pharmacists: modelling the organizational and economic impacts of new human papilloma virus (HPV) vaccine pathways in France</u>

The vaccine coverage rate (VCR) for human papillomavirus (HPV) in France is one of the lowest in Europe, well below the target of 80% announced in the French Cancer Plan 2021–2030. The extension of vaccination...

Authors: Bruno Julia, Claire Foerst, Sarah Akarkoub, Sarah Azzazene, Nathalie Grémaud, Romain Olivier Sénégas, Benoit Mourlat, Carole Mamane, Lionel Bensimon and Gaëlle Farge

Citation: BMC Health Services Research 2024 24:845 Content type: Research Published on: 25 July 2024

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 27 July 2024)
[No new digest content identified]

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 27 July 2024)

Ethical considerations during Mpox Outbreak: a scoping review

Historically, epidemics have been accompanied by the concurrent emergence of stigma, prejudice, and xenophobia. This scoping review aimed to describe and map published research targeting ethical values concern...

Authors: Fatma Badr El Dine, Assem Gebreal, Dalia Samhouri, Haimanot Estifanos, Islam Kourampi, Hasnaa Abdelrhem, Hamed Abdelma'aboud Mostafa, Ahmed Gamal Elshaar, Tarun Kumar Suvvari and

Ramy Mohamed Ghazy

Citation: BMC Medical Ethics 2024 25:79

Content type: Research Published on: 22 July 2024

BMC Medicine

http://www.biomedcentral.com/bmcmed/content (Accessed 27 July 2024) [No new digest content identified]

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 27 July 2024) [No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles (Accessed 27 July 2024)

Exploring the perceptions and experiences of mobile teams on COVID-19 vaccine uptake at the community level: evidence from Benue and Niger states

As part of the fight against coronavirus disease, Nigeria received nearly 4 million doses of the COVID-19 vaccine via the COVID-19 Vaccines Global Access (COVAX) Facility, marking a historic step towards equit...

Authors: Saheed Dipo Isiaka, Akolade Uthman Jimoh, Olugbemisola Wuraola Samuel, Sunday Atobatele, Sidney Sampson, Joshua Cinwonsoko David, Irene Okoye, Zubair Adegoke, Victor Daniel and Sunday Nto

Citation: BMC Public Health 2024 24:1996

Content type: Research Published on: 25 July 2024

<u>Determinants of wealth-related inequalities in full vaccination coverage among children in Nepal: a decomposition analysis of nationally representative household survey data</u>

Over the past two decades, child health indicators in Nepal have improved significantly at the national level. Yet, this progress hasn't been uniform across various population subsets. This study identified th...

Authors: Barun Kumar Singh and Resham B. Khatri

Citation: BMC Public Health 2024 24:1990

Content type: Research Published on: 25 July 2024

Childhood vaccination among Polish immigrants in Norway: a qualitative study

Confidence in childhood vaccination is high in Norway and the Norwegian Childhood Immunization Programme (NCIP) achieves high overall coverage rates. However, lower coverage has been observed for some immigran...

Authors: Rebecca Nybru Gleditsch, Kamila Hynek, Bo T. Hansen, Trine Skogset Ofitserova, Brita

Askeland Winje and Thea Steen Skogheim Citation: BMC Public Health 2024 24:1978

Content type: Research Published on: 24 July 2024

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 27 July 2024) [No new digest content identified]

BMJ Evidence-Based Medicine

August 2024 - Volume 29 - 4 https://ebm.bmj.com/content/29/4 Original research

<u>Trivalent and quadrivalent seasonal influenza vaccine in adults aged 60 and older: a systematic review and network meta-analysis</u> (10 April, 2024)

Areti Angeliki Veroniki, Sai Surabi Thirugnanasampanthar, Menelaos Konstantinidis, Jasmeen Dourka, Marco Ghassemi, Dipika Neupane, Paul Khan, Vera Nincic, Margarita Corry, Reid Robson, Amanda Parker, Charlene Soobiah, Angela Sinilaite, Pamela Doyon-Plourde, Anabel Gil, Winnie Siu, Nasheed Moqueet, Adrienne Stevens, Kelly English, Ivan D Florez, Juan J Yepes-Nuñez, Brian Hutton, Matthew Muller, Lorenzo Moja, Sharon Straus, Andrea C Tricco

BMJ Global Health

July 2024 - Volume 9 - 7 https://gh.bmj.com/content/9/7 [Reviewed earlier]

Bulletin of the Atomic Scientists

July 2024 https://thebulletin.org/magazine/2024-07/ [Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(7); 2024 Jul 1 https://www.ncbi.nlm.nih.gov/pmc/issues/465389/ [Reviewed earlier]

Cell

Jul 11, 2024 Volume 187 Issue 14 p3461-3786 https://www.cell.com/cell/current 50th Anniversary
[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 4 July 2024 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 116, Issue 1 Pages: 1-256 July 2024 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current [Reviewed earlier]

Clinical Therapeutics

June 2024 Volume 46 Issue 6 p441-516 http://www.clinicaltherapeutics.com/current EDITORIAL

<u>The Importance of Ongoing Surveillance, Education, and Due Diligence for Antimicrobial Stewardship</u>

Jill L. Maron Published online: July 04, 2024 p441

Clinical Trials

Volume 21 Issue 3, June 2024 https://journals.sagepub.com/toc/ctja/21/3 [Reviewed earlier]

Conflict and Health

http://www.conflictandhealth.com/ [Accessed 27 July 2024] [No new digest content identified]

Contemporary Clinical Trials

Volume 142 July 2024 https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/142/suppl/C [Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 3 / June 2024

https://www.liebertpub.com/toc/crispr/7/3 [Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023 https://link.springer.com/journal/40142/volumes-and-issues/11-3 [Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 7 2024 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

August 2024 - Volume 37 - Issue 4 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx [Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 27 July 2024] [No new digest content identified]

Developing World Bioethics

Volume 24, Issue 2 Pages: 49-134 June 2024 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

Development in Practice

Volume 34, Issue 4, 2024 https://www.tandfonline.com/toc/cdip20/34/4 [Reviewed earlier]

Development Policy Review

Volume 42, Issue 4 July 2024 https://onlinelibrary.wiley.com/toc/14677679/current [Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

Disasters

Volume 48, Issue 3 July 2024 https://onlinelibrary.wiley.com/toc/14677717/2024/48/3 [Reviewed earlier]

EMBO Reports

Volume 25 Issue 7 11 July 2024 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 7—July 2024 http://wwwnc.cdc.gov/eid/ [Reviewed earlier]

Epidemics

Volume 47 June 2024 https://www.sciencedirect.com/journal/epidemics/vol/47/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 4 Pages: 1-51 July—August 2024 https://onlinelibrary.wiley.com/toc/25782363/current

Research with refugee populations Ethical considerations for crowdsourced research [Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023 https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue [Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023) https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C [Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 3, June 2024 https://academic.oup.com/eurpub/issue/34/3 [Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

July/August 2024 Volume 103, Number 4 https://www.foreignaffairs.com/issues/2023/103/4 [Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 2 http://www.tandfonline.com/toc/sfds20/current [Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 7 July 2024 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/7 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles [Accessed 27 July 2024] [No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 3 June 27, 2024 http://www.ghspjournal.org/content/current [Reviewed earlier]

Global Legal Monitor & Legal Reports - Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 27 July 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/ [Accessed 27 July 2024] [No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024
https://www.hhrjournal.org/volume-26-issue-1-june-2024/
SPECIAL SECTION - COMMEMORATING 30 YEARS
[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 2 - April 2024 https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 6, July 2024 https://academic.oup.com/heapol/issue/39/6 [Reviewed earlier]

Health Research Policy and Systems

http://www.health-policy-systems.com/content [Accessed 27 July 2024] [No new digest content identified]

Human Gene Therapy

Volume 35, Issue 13-14 / July 2024 https://www.liebertpub.com/toc/hum/35/13-14 [New issue; No digest content identified]

Humanitarian Practice Network

https://odihpn.org/ Featured Publications [No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024 https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList Selected Content [Reviewed earlier]

Immunity

Jun 11, 2024 Volume 57 Issue 6 p1177-1442 https://www.cell.com/immunity/current [Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/ [Accessed 27 July 2024] [No new digest content identified]

Infectious Diseases of Poverty

http://www.idpjournal.com/content [Accessed 27 July 2024] [No new digest content identified]

International Health

Volume 16, Issue 4, July 2024 https://academic.oup.com/inthealth/issue/16/4 [Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024): https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml **Special Issue on Inter-State Communications**Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 7 (2024): July 2024 https://www.ijcmph.com/index.php/ijcmph/issue/view/114 [Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 3, June 2024 https://academic.oup.com/ije/issue/53/3 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024 https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1 Table of contents [Reviewed earlier]

JAMA

July 23/30, 2024, Vol 332, No. 4, Pages 265-346 https://jamanetwork.com/journals/jama/currentissue [New issue; No digest content identified]

JAMA Health Forum

July 2024, Vol 5, No. 7 https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

JAMA Pediatrics

July 2024, Vol 178, No. 7, Pages 635-732 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

JBI Evidence Synthesis

July 2024 - Volume 22 - Issue 7 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [New issue; No digest content identified]

Journal of Adolescent Health

July 2024 Volume 75 Issue 1 p1-206 https://www.jahonline.org/current [Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 80 (2024)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 3 June 2024 https://link.springer.com/journal/10900/volumes-and-issues/49-3 [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024, Page 1988-1996

https://www.cmro.in/index.php/jcmro/issue/view/75
[Reviewed earlier]

Journal of Development Economics

Volume 170 September 2024 https://www.sciencedirect.com/journal/journal-of-development-economics/vol/170/suppl/C [New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 1-2, February–April 2024 http://journals.sagepub.com/toc/jre/current [Reviewed earlier]

Journal of Epidemiology & Community Health

July 2024 - Volume 78 - 7 https://jech.bmj.com/content/78/7 [New issue; No digest content identified]

Journal of Evidence-Based Medicine

Volume 17, Issue 2 Pages: 237-467 June 2024 https://onlinelibrary.wiley.com/toc/17565391/current [Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 1 (2024) http://www.tandfonline.com/toc/rjge20/current [Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 2, May 2024 https://muse.jhu.edu/issue/52595

Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 3 June 2024 https://link.springer.com/journal/10903/volumes-and-issues/26-3 [Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 3 https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

Journal of International Development

Volume 36, Issue 5 Pages: 3-2503 July 2024 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

Journal of Medical Ethics

July 2024 - Volume 50 - 7 http://jme.bmj.com/content/current [Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

The Journal of Pediatrics

Volume 269 June 2024 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/269/suppl/C [Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1 https://www.tandfonline.com/toc/jppp20/17/1 [Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2024 - Volume 30 - Issue 4 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 2, June 2024 https://link.springer.com/journal/41271/volumes-and-issues/45-2 [Reviewed earlier]

Journal of the Royal Society - Interface

July 2024 Volume 21 Issue 216 https://royalsocietypublishing.org/toc/rsif/current [Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 5, July 2024 https://academic.oup.com/jtm/issue [Reviewed earlier]

Journal of Virology

Volume 98 • Number 6 • June 2024 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

Jul 27, 2024 Volume 404 Number 10450 p311-404 https://www.thelancet.com/journals/lancet/issue/current Editorial

Dengue: the threat to health now and in the future

The Lancet

The Lancet Child & Adolescent Health

July 2024 Volume 8 Number 7 p467-544 https://www.thelancet.com/journals/lanchi/issue/current [Reviewed earlier]

Lancet Digital Health

Jul 2024 Volume 6 Number 7 e433-e535 https://www.thelancet.com/journals/landig/issue/current [Reviewed earlier]

Lancet Global Health

Jul 2024 Volume 12 Number 7 e1068-e1213 https://www.thelancet.com/journals/langlo/issue/current [Reviewed earlier]

Lancet Infectious Diseases

Jul 2024 Volume 24 Number 7 p665-792, e416-e472 https://www.thelancet.com/journals/laninf/issue/current [Reviewed earlier]

Lancet Public Health

Jul 2024 Volume 9 Number 7 e411-e532 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Jul 2024 Volume 12 Number 7 p499-574, e42 https://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 7 July 2024 https://link.springer.com/journal/10995/volumes-and-issues/28-7 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 5, July 2024 http://mdm.sagepub.com/content/current [New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 102, Issue 2 Pages: 271-516 June 2024 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Jul 03, 2024 Volume 32 Issue 7 p2037-2426 https://www.cell.com/molecular-therapy/current [Reviewed earlier]

Nature

Volume 631 Issue 8022, 25 July 2024 https://www.nature.com/nature/volumes/631/issues/8022 Editorial 24 Jul 2024

Science must protect thinking time in a world of instant communication

E-mails and instant messaging are core to research — but also a distraction. Researchers should study their impact on science, and how they can claw back time to concentrate.

News & Views 24 Jul 2024

AI produces gibberish when trained on too much AI-generated data

Generative AI models are now widely accessible, enabling everyone to create their own machinemade something. But these models can collapse if their training data sets contain too much AIgenerated content.

Emily Wenger

Article Open Access 24 Jul 2024

AI models collapse when trained on recursively generated data

Analysis shows that indiscriminately training generative artificial intelligence on real and generated content, usually done by scraping data from the Internet, can lead to a collapse in the ability of the models to generate diverse high-quality output.

Ilia Shumailov, Zakhar Shumaylov, Yarin Gal

Abstract

Stable diffusion revolutionized image creation from descriptive text. GPT-2 (ref. 1), GPT-3(.5) (ref. 2) and GPT-4 (ref. 3) demonstrated high performance across a variety of language tasks. ChatGPT introduced such language models to the public. It is now clear that generative artificial intelligence (AI) such as large language models (LLMs) is here to stay and will substantially change the ecosystem of online text and images. Here we consider what may happen to GPT-{n} once LLMs contribute much of the text found online. We find that indiscriminate use of model-generated content in training causes irreversible defects in the resulting models, in which tails of the original content distribution disappear. We refer to this effect as 'model collapse' and show that it can occur in LLMs as well as in variational autoencoders (VAEs) and Gaussian mixture models (GMMs). We build theoretical intuition behind the phenomenon and portray its ubiquity among all learned generative models. We demonstrate that it must be taken seriously if we are to sustain the benefits of training from large-scale data scraped from the web. Indeed, the value of data collected about genuine human interactions with systems will be increasingly valuable in the presence of LLM-generated content in data crawled from the Internet.

Nature Biotechnology

Volume 42 Issue 7, July 2024 https://www.nature.com/nbt/volumes/42/issues/7 [Reviewed earlier]

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed27 July 2024) [No new digest content identified]

Nature Genetics

Volume 56 Issue 7, July 2024 https://www.nature.com/ng/volumes/56/issues/7 [Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 7, July 2024

https://www.nature.com/nathumbehav/volumes/8/issues/7

World View 03 Jul 2024

Why scientific integrity matters now more than ever

This year, 49% of the world will go to the polls. Political support for science-informed policy is not a given. Maria Caffrey, a whistleblower who defended scientific integrity under the Trump administration, offers advice on media engagement during this time.

Maria A. Caffrey

World View 01 Jul 2024

Ethics committees promote responsible research in China

Guoyu Wang leads and serves on Chinese ethics committees. She explains how research ethics have developed in China, and why ethics review promotes responsible innovation. Guoyu Wang

Nature Medicine

Volume 30 Issue 7, July 2024 https://www.nature.com/nm/volumes/30/issues/7 [Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 7, July 2024 https://www.nature.com/nrd/volumes/23/issues/7 [Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 7, July 2024 https://www.nature.com/nrg/volumes/25/issues/7 [Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 7, July 2024 https://www.nature.com/nri/volumes/24/issues/7 [Reviewed earlier]

New England Journal of Medicine

Volume 391 No. 4 July 25, 2024 https://www.nejm.org/toc/nejm/medical-journal Review Article CME

HIV-Associated Tuberculosis

G. Meintjes and G. Maartens

NEJM Evidence

Volume 3 No. 8 August 2024

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[New issue; No digest content identified]

njp Vaccines

https://www.nature.com/npjvaccines/

[Accessed 27 July 2024]

Article

A scoping review of global COVID-19 vaccine hesitancy among pregnant persons

27 July 2024

Imaima Casubhoy, Alyssa Kretz, Rosemary Morgan

Brief Communication Published: 16 July 2024

Standardized immunological assays for assessing COVID-19 vaccines by the CEPI-

Centralized Laboratory Network

Ali Azizi, Deborah Ogbeni, Valentina Bernasconi

Pediatrics

Volume 154, Issue 1 July 2024 https://publications.aap.org/pediatrics/issue/154/1 [Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 7 July 2024 https://link.springer.com/journal/40273/volumes-and-issues/42-7 [New issue; No digest content identified]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 27 July 2024) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 27 July 2024) [No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE NEWEST FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 27 July 2024)

<u>Estimating immunization coverage at the district level: A case study of measles and diphtheria-pertussis-tetanus-Hib-HepB vaccines in Ethiopia</u>

Latera Tesfaye, Tom Forzy, Fentabil Getnet, Awoke Misganaw, Mesfin Agachew Woldekidan, Asrat Arja Wolde, Samson Warkaye, Solomon Kassahun Gelaw, Solomon Tessema Memirie, Tezera Moshago Berheto, Asnake Worku, Ryoko Sato, Nathaniel Hendrix, Meseret Zelalem Tadesse, Yohannes Lakew Tefera, Mesay Hailu, Stéphane Verguet

Research Article | published 25 Jul 2024 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0003404

Measuring what matters: Context-specific indicators for assessing immunisation performance in Pacific Island Countries and Areas

Cyra Patel, Ginny M. Sargent, Adeline Tinessia, Helen Mayfield, Dan Chateau, Akeem Ali, Ilisapeci Tuibeqa, Meru Sheel

Research Article | published 25 Jul 2024 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0003068

PLoS Medicine

http://www.plosmedicine.org/ (Accessed 27 July 2024) [No new digest content identified]

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 27 July 2024) [No new digest content identified]

PLoS One

http://www.plosone.org/ [Accessed 27 July 2024]

<u>Latinx youth's and parents' covid-19 beliefs, vaccine hesitancy and vaccination rates:</u> <u>Longitudinal associations in a community sample</u>

Namoonga M. Mantina, Maiya G. Block Ngaybe, Katharine H. Zeiders, Kayla M. Osman, Ada M. Wilkinson-Lee, Antoinette M. Landor, Lindsay T. Hoyt Research Article | published 24 Jul 2024 PLOS ONE https://doi.org/10.1371/journal.pone.0307479

<u>Estimation of COVID-19 vaccine effectiveness against infections and severe outcomes</u> using routine surveillance data in Kosovo, July—September 2021

Albiona Rashiti-Bytyçi, Emily White Johansson, Pranvera Kaçaniku-Gunga, Kostas Danis, Anja Schoeps, Achim Dörre, Fetije Fetaj, Arijana Kalaveshi Research Article | published 24 Jul 2024 PLOS ONE https://doi.org/10.1371/journal.pone.0305629

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 27 July 2024]

PNAS - Proceedings of the National Academy of Sciences of the United States

July 23, 2024 vol. 121 no. 30

https://www.pnas.org/toc/pnas/121/30 [New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 6, June 2024 https://academic.oup.com/pnasnexus/issue/3/6 [Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 2 - April 2024 https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [Reviewed earlier]

Preventive Medicine

Volume 184 July 2024 https://www.sciencedirect.com/journal/preventive-medicine/vol/184/suppl/C [Reviewed earlier]

Proceedings of the Royal Society B

July 2024 Volume 291 Issue 2026 https://royalsocietypublishing.org/toc/rspb/current [Reviewed earlier]

Public Health

Volume 232 Pages 1-208 (July 2024) https://www.sciencedirect.com/journal/public-health/vol/232/suppl/C [New issue; No digest content identified]

Public Health Ethics

Volume 17, Issue 1-2, April/July 2024 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1 https://karger.com/phg/issue/27/1 [Reviewed earlier]

Public Health Reports

Volume 139 Issue 4, July/August 2024 https://journals.sagepub.com/toc/phrg/139/4 [New issue; No digest content identified]

Qualitative Health Research

Volume 34 Issue 7, June 2024 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 20 Issue 3, July 2024 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 27 July 2024] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 23 Jul 2024

<u>Status of the national immunization technical advisory groups in the Americas:</u>
<u>recommendations for improvement</u>

Original research | English |

Risk Analysis

Volume 44, Issue 7 Pages: 1535-172 July 2024 https://onlinelibrary.wiley.com/toc/15396924/current [New issue; No digest content identified]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 27 July 2024] [Reviewed earlier]

Science

Volume 385| Issue 6707| 26 Jul 2024 https://www.science.org/toc/science/current

Editorial

Neutrality's effects on academic freedom

BY H. Holden Thorp 25 Jul 2024: 347

The idea that universities in the United States—and especially their presidents—should be politically neutral was taking hold long before their recent struggles in responding to the Israel—Hamas war. A document called the <u>Kalven Report</u> that was produced at the University of Chicago in 1967 famously declared that "the university is the home and sponsor of critics; it is not itself the critic." Thus, in matters of political controversy, the university best serves its faculty and students by remaining neutral so that those with disciplinary expertise can opine freely. Neutrality makes good sense when it comes to political issues that by their nature are matters of opinion. But what about matters of science, especially when a finding has powerful political implications such as studies on climate or vaccines? Where should universities draw the line?

The proponents of blanket neutrality assert that universities should not only stay out of geopolitical matters but should also not comment on findings of their faculty's research if they are politically sensitive. But does that paint the issue with too broad a brush? There is a distinction between the science itself and opinions about whether and how to act on it. The results of a vaccine trial are neutral—however, the role of government in mandating vaccines is political.

Peter Hans, president of the 17-campus University of North Carolina system, told me he would not support or oppose a particular scientific finding but "will defend all day the faculty's right to share that finding with the world." Jenna Robinson, a staunch proponent of neutrality and president of the conservative James G. Martin Center for Academic Renewal, went even further, saying to me, "I think it's *better* for presidents not to comment on the content of the research (italics hers)." And University of Chicago president Paul Alivisatos, also a renown nanoscientist, told me that the proper approach is wholesale neutrality, with the university standing as a place where "both popular and dissenting viewpoints are thoughtfully subject to reason and evidenced debate. A president seeking to foreclose debates by issuing institutional proclamations will inadvertently erode the credibility of the university in the eyes of the public and policy-makers alike."

Many critics of neutrality are disheartened by this hands-off approach. The prolific biomedical scientist Eric Topol described the stance to me as "a consistent path of being spineless, hiding in plain sight, ducking controversy, appearing to be dissociated from faculty and the science that they publish." It's discouraging that institutions can validate the scientific research of faculty by hiring and promoting them but then opt for neutrality if the findings have political implications. I don't fault the presidents for adopting this position—the polarizing politics of the moment gives them little choice. But it is a major shift from an era when university presidents were regarded as both academic and moral leaders who stood up for the truth in times of crisis.

For the scientists themselves, university neutrality is a two-edged sword. It comes with a strong commitment by administrators to back the rights of faculty to carry out their research, wherever the results may lead, but the trade-off is that if the findings are politically sensitive, the institution is going to stay out of the fray.

If neutrality is to be the order of the day, then scientists need to take extra care not to be intimidated when their research ignites a political storm. Dartmouth College President Sian Beilock put it like this: "I think a scientist's job is to do the best work they can and publish the findings that they believe will be most impactful to humanity," she said, "regardless of whether their conclusions align with one particular idea."

At the same time, scientists need to hold the institutions accountable for their commitments to stand behind their researchers in every other way. True neutrality means that institutions would not take actions to defund or deemphasize research because it is controversial, but there are worrying signs that this is already happening. Stanford University just shut down its disinformation research program after it was hit by lawsuits from conservative groups. Unless this reciprocity holds, there is a danger that universities will shirk their responsibility to stand up not for any particular finding but for a more overriding principle—the importance of independent scholarship.

Science and Engineering Ethics

Volume 30, Issue 3 June 2024 https://link.springer.com/journal/11948/volumes-and-issues/30-3 [Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 757| 24 Jul 2024 https://www.science.org/toc/stm/current Viewpoint

Improving vaccine equity by increasing vaccine thermostability

BY Jonathan Hare, et al.

24 Jul 20

Abstract

The development, manufacture, and deployment of new vaccine technologies to combat SARS-CoV-2 enabled an unparalleled rapid response to the emerging health threat. However, the unequal global distribution of these vaccines highlighted a major gap in existing thermotolerance profiles and cold chain infrastructure that needs to be addressed to maximize their global health impact.

Scientific Reports

https://www.nature.com/srep/articles?type=article [Accessed 27 July 2024] [No new digest content identified]

Social Science & Medicine

Volume 350 June 2024 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/350/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 27 July 2024] [No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 4 August 2024 https://link.springer.com/journal/11017/volumes-and-issues/45-4

Travel Medicine and Infectious Diseases

Volume 60 July-August 2024

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/60/suppl/C

[New issue; No digest content identified]

Tropical Medicine & International Health

Volume 29, Issue 7 Pages: i-iv, 541-656 July 2024 https://onlinelibrary.wiley.com/toc/13653156/current

[New issue; No digest content identified]

Vaccine

Volume 42, Issue 19 Pages 3931-4088 (25 July 2024)

https://www.sciencedirect.com/journal/vaccine/vol/42/issue/19

Selected Content

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/59/suppl/C

[Reviewed earlier]

Vaccines

https://www.mdpi.com/journal/vaccines

[Accessed 27 July 2024]

Open Access Article

<u>Exploring the Inherent Heterogeneity of Vaccine Hesitancy: A Study of a Childhood-Vaccine-Hesitant Population</u>

by Monika Lamot, Andrej Kirbiš and Mitja Vrdelja

Vaccines 2024, 12(8), 839; https://doi.org/10.3390/vaccines12080839 - 25 Jul 2024 Abstract

Vaccine hesitancy and its determinants have been previously widely researched. Vaccine hesitancy has been defined as a continuum of attitudes, ranging from accepting vaccines with doubts to rejecting them. The present study aims to explore the heterogeneity of a childhood-vaccine-hesitant group by using

Open Access Review

<u>Challenges for Sustaining Measles Elimination: Post-Verification Large-Scale Import-Related Measles Outbreaks in Mongolia and Cambodia, Resulting in the Loss of Measles Elimination Status</u>

by José Hagan, Otgonbayar Dashpagma, Ork Vichit, Samnang Chham, Sodbayar Demberelsuren, Varja Grabovac, Shafiqul Hossain, Makiko Iijima, Chung-won Lee, Anuzaya Purevdagva, Kayla Mariano, Roger Evans, Yan Zhang and Yoshihiro Takashima

Vaccines 2024, 12(7), 821; https://doi.org/10.3390/vaccines12070821 - 22 Jul 2024 Abstract

The Western Pacific Region's pursuit of measles elimination has seen significant progress and setbacks. Mongolia and Cambodia were the first two middle-income countries in the Western Pacific to be verified as having eliminated measles by the Western Pacific Regional Verification Commission for Measle

Open Access Review

Possible Paths to Measles Eradication: Conceptual Frameworks, Strategies, and Tactics

by Amy K. Winter and William J. Moss

Vaccines 2024, 12(7), 814; https://doi.org/10.3390/vaccines12070814 - 22 Jul 2024 Abstract

Measles elimination refers to the interruption of measles virus transmission in a defined geographic area (e.g., country or region) for 12 months or more, and measles eradication refers to the global interruption of measles virus transmission. Measles eradication was first discussed and debated...

Value in Health

July 2024 Volume 27 Issue 7 p821-998 https://www.valueinhealthjournal.com/current [Reviewed earlier]

World Development

Volume 179 July 2024 https://www.sciencedirect.com/journal/world-development/vol/179/suppl/C [Reviewed earlier]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Pre-Print Servers

Gates Open Research

https://gatesopenresearch.org/browse/articles [Accessed 27 July 2024] Research Article metrics AWAITING PEER REVIEW No new digest content identified.

medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 27 July 2024] [Filter: All articles]

Optimal annual COVID-19 vaccine boosting dates following previous booster vaccination or breakthrough infection

Jeffrey P Townsend, Hayley B. Hassler, Alex Dornburg medRxiv 2024.07.25.24311016; doi: https://doi.org/10.1101/2024.07.25.24311016

A central research portal for mining pancreatic clinical and molecular datasets and accessing biobanked samples

Jorge Oscanoa, Helen Ross-Adams, Abu Z M Dayem Ullah, Trupti S Kolvekar, Lavanya Sivapalan, Emanuela Gadaleta, Graeme J Thorn, Maryam Abdollahyan, Ahmet Imrali, Amina Saad, Rhiannon Roberts, Christine Hughes, PCRFTB, Hemant M Kocher, Claude Chelala medRxiv 2024.07.25.24309825; doi: https://doi.org/10.1101/2024.07.25.24309825

<u>Effectiveness Over Time of a Primary Series of the Original Monovalent COVID-19 Vaccines in Adults in the United States</u>

J. Bradley Layton, Patricia C Lloyd, Lauren S Peetluk, Yixin Jiao, Djeneba Audrey Djibo, Joann F Gruber, Jie Deng, Christine Bui, An-Chi Lo, Rachel P Ogilvie, Ron Parambi, Michael E Miller, Jennifer Song, Lisa B Weatherby, Sylvia Cho, Hui Lee Wong, Tainya C Clarke, Jessica Rose Hervol, Dóra Illei, Elizabeth J Bell, Grace Wenya Yang, John D Seeger, Michael Wernecke, Morgan M Richey, Richard A Forshee, Steven A Anderson, Yoganand Chillarige, Cheryl N McMahill-Walraven, Kandace L Amend, Mary S Anthony, Azadeh Shoaibi

medRxiv 2024.07.24.24310878; doi: https://doi.org/10.1101/2024.07.24.24310878

Technology transfer of a dried blood virus neutralization assay to a GAVI-eligible country

Evangeline Obodai, Jonne Terstappen, Jude Y. Mensah, Anouk Versnel, Comfort N. Antwi, Louis J. Bont, Daniela Cianci, Eveline M. Delemarre, John K. Odoom, Peter M. van de Ven, Natalie I. Mazur medRxiv 2024.07.23.24310857; doi: https://doi.org/10.1101/2024.07.23.24310857 ABSTRACT

Background Global health clinical research is commonly led by high-income countries (HICs) as lowand middle-income countries face barriers to participate, including lack of financial and human capacity and lack of research environment. Respiratory syncytial virus (RSV) vaccine development is also led by HICs, preventing global vaccine access while LMICs carry the burden of life-threatening disease. This study aims to transfer an RSV neutralization assay, which uses live cells and virus with inherent high variation, to a GAVI-eligible country.

Methods Using a train-the-trainer approach, a Ghanaian researcher was trained in the Netherlands on the dried blood-based RSV neutralization assay. Subsequently, a Dutch researcher visited Ghana to support the process of adapting the technique to the Ghanaian setting. In a previously validated RSV neutralization assay on dried blood, Hep-2 cells were infected with a serial dilution of sample-virus mixture to determine the half-maximal inhibitory concentration. Fifty-one dried blood and serum samples were tested in parallel in both countries to assess concordance.

Results Training and technology transfer was deemed successful, which was defined as neutralization measurements by the Ghana team and high concordance (Lin's concordance correlation coefficient (CCC) > 0.8). Neutralizing capacity measured in identical samples in Ghana and the Netherlands correlated highly (Lin's CCC = 0.87; Spearman rho = 0.89) but was systematically lower in Ghana than the Netherlands.

Conclusion We show successful strengthening of the laboratory research capacity in a GAVI-eligible country. Reliable measurement of RSV neutralizing antibodies in a GAVI-eligible country and the use of dried blood can contribute to inclusion of LMICs in RSV vaccine development and access.

Estimating the impact of the RTS,S/AS01 malaria vaccine in Benin: A mathematical modelling study

Sena Alohoutade, Rachel Hounsell, Sheetal Silal

medRxiv 2024.07.20.24310712; doi: https://doi.org/10.1101/2024.07.20.24310712

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences [Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-No new digest content identified.

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles [Accessed 27 July 2024] Selected Research Study Protocol Open Access

Power Relations in Optimisation of Therapies and Equity in Access to Antibiotics (PROTEA)
Study: investigating the intersection of socio-economic and cultural drivers on
antimicrobial resistance (AMR) and its influence on healthcare access and health-providing
behaviours in India and South Africa

[version 1; peer review: awaiting peer review]

Esmita Charani, et al.

Abstract

Across social structures within society, including healthcare, power relations manifest according to gender, socioeconomic status, race, ethnicity, and class influencing infection related healthcare access and health providing-behaviours. Therefore, accounting for sociocultural drivers, including gender, race, and class, and their influence on economic status can improve healthcare access and health-providing behaviours in infection prevention and control (IPC) as well as antibiotic use, which in turn helps mitigate the spread of antimicrobial resistance (AMR).

This Wellcome funded research will investigate how and why the social determinants of health and economic status influence how people seek, experience, and provide healthcare for suspected or proven (bacterial) infections and how these factors influence antibiotic prescribing and use in South Africa (upper middle-income country) and India (lower middle-income country). The aim of this body of work is to, (1) define and estimate the sociocultural and economic drivers for AMR in different resource settings, (2) design, implement and evaluate context-sensitive IPC and antimicrobial stewardship (AMS) interventions, and (3) inform policy and strategy for AMR mitigation. The population will be healthcare workers (HCWs), patients, and their carers across acute medical and surgical pathways where IPC and antibiotic-related healthcare access and health-providing behaviours will be studied...

* * * *

Think Tanks

Brookings [to 27 July 2024] http://www.brookings.edu/ Research No new digest content identified.

Center for Global Development [to 27 July 2024]

https://www.cgd ev.org/ All Research BRIEFS

Why and How the G20 Should Supercharge Research Publishing Reform

Anastassia Demeshko et al.

July 24, 2024

The movement towards Open Access research is part of a broader vision for Open Science, championed by multilateral initiatives, notably UNESCO, and various G20 convenings. While this movement has achieved some progress by reducing paywalls, gains have been modest and slow and, more importantly, have...

Chatham House [to 27 July 2024]

https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

Council on Foreign Relations [to 27 July 2024]

https://www.cfr.org/media/news-releases
New Releases [Selected]
No new digest content identified.

CSIS [to 27 July 2024] https://www.csis.org/ Reports [Selected]

Prioritizing Health System Development in the Pacific: A Layered Approach

A more strategic and holistic U.S. approach to healthcare system development in the Pacific Islands region could transform lives, boost regional stability, and cement American partnerships across the region.

Brief by Kathryn Paik and Eileen Natuzzi — July 24, 2024

Kaiser Family Foundation [to 27 July 2024]

https://www.kff.org/search/?post_type=press-release Newsroom No new digest content identified.

McKinsey Global Institute [to 27 July 2024]

https://www.mckinsey.com/mgi/overview

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 27 July 2024]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

Pew Research Center [to 27 July 2024]

https://www.pewresearch.org/

Latest Publications [Selected] No new digest content identified.

Rand [to 27 July 2024]

https://www.rand.org/pubs.html Published Research [Selected]

<u>Testing an Intervention to Improve Health Care Worker Well-Being During the COVID-19</u>

<u>Pandemic: A Cluster Randomized Clinical Trial</u>

In this cluster randomized clinical trial (RCT), we aimed to evaluate the effectiveness of a tailored peer-to-peer support intervention for health care workers during the pandemic.

Jul 24, 2024

Spatial Accessibility and Uptake of Pediatric COVID-19 Vaccinations by Social Vulnerability An examination of how the spatial accessibility of COVID-19 vaccination sites affects COVID-19 pediatric vaccine uptake.

Jul 24, 2024

Abstract

Background and Objectives

Geographic accessibility predicts pediatric preventive care utilization, including vaccine uptake. However, spatial inequities in the pediatric coronavirus disease 2019 (COVID-19) vaccination rollout remain underexplored. We assessed the spatial accessibility of vaccination sites and analyzed predictors of vaccine uptake.

Methods

In this cross-sectional study of pediatric COVID-19 vaccinations from the US Vaccine Tracking System as of July 29, 2022, we described spatial accessibility by geocoding vaccination sites, measuring travel times from each Census tract population center to the nearest site, and weighting tracts by their population demographics to obtain nationally representative estimates. We used quasi-Poisson regressions to calculate incidence rate ratios, comparing vaccine uptake between counties with highest and lowest quartile Social Vulnerability Index scores: socioeconomic status (SES), household composition and disability (HCD), minority status and language (MSL), and housing type and transportation.

Results

We analyzed 15,233,956 doses administered across 27,526 sites. Rural, uninsured, white, and Native American populations experienced longer travel times to the nearest site than urban, insured, Hispanic, Black, and Asian American populations. Overall Social Vulnerability Index, SES, and HCD were associated with decreased vaccine uptake among children aged 6 months to 4 years (overall: incidence rate ratio 0.70 [95% confidence interval 0.60-0.81]; SES: 0.66 [0.58-0.75]; HCD: 0.38 [0.33-0.44]) and 5 years to 11 years (overall: 0.85 [0.77-0.95]; SES: 0.71 [0.65-0.78]; HCD: 0.67 [0.61-0.74]), whereas social vulnerability by MSL was associated with increased uptake (6 months-4 years: 5.16 [3.59-7.42]; 5 years-11 years: 1.73 [1.44-2.08]).

Conclusions

Pediatric COVID-19 vaccine uptake and accessibility differed by race, rurality, and social vulnerability. National supply data, spatial accessibility measurement, and place-based vulnerability indices can be applied throughout public health resource allocation, surveillance, and research.

Distilling the Fundamentals of Evidence-Based Public Health Policy

Public health policy interventions have historically driven many significant public health advancements. In this discussion, we outline the key characteristics and benefits that set these interventions apart from programmatic approaches.

Urban Institute [to 27 July 2024]
https://www.urban.org/publications
New Research Publications - Selected

World Economic Forum [to 27 July 2024]

https://agenda.weforum.org/press/
Media [Selected]
No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

<u>Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.</u>

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Public consultation dates [announced to date]:

NMPA, China - Deadline for comments by 12 October 2024 TFDA, Chinese Taipei - Deadline for comments by 30 September 2024 ANVISA, Brazil - Deadline for comments by 24 August 2024 MHLW/PMDA, Japan - Deadline for comments by 28 July Republic of Korea - Deadline for comments by 15 July 2024

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

::::::

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.